Tenderwize
Back to tender search

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 193 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

60/100

Opportunity Score

PromisingLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

20 / 100

Risk factors

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Strong opportunity

Key Facts

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Pharmaceutical discount contract for Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))
  • Supply of the drug under uniform conditions set by TK
Show full summary

Open House procedure by Techniker Krankenkasse (TK) for discount contracts on the drug Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R)) under §130c SGB V. The procedure allows continuous joining during the contract term (max 24 months from March 2025 to February 2027). No estimated value provided; no competition or award criteria; eligibility requires being a pharmaceutical entrepreneur with authorization for the drug. Submission is by email (with qualified electronic signature) or post. Documents are available but were not analyzed.

Risks

The contract ends automatically at the end of the month when the patent or market exclusivity for the drug expires, pot...

Documents must be signed with a qualified electronic signature if sent by email; if not possible, postal original copy...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG with respect to the offered drug
  • Must have a valid marketing authorization for the drug in Germany or be otherwise entitled to market it

Eligibility

  • Must provide a self-declaration confirming eligibility and no exclusion grounds

Requirements may be incomplete.

Award Criteria

Lot 1

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (1)

LOT-0001

Open House Originale Rabattverträge 2025-01 - Bictegravir/Emtricitabin/Tenofoviralafenamid (Biktarvy(R))

Discount contracts for the combination drug Bictegravir/Emtricitabin/Tenofoviralafenamid. Continuous enrollment; no exclusivity; standard conditions.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Feb 2025 - Feb 2027

Category

Pharmaceutical products

Award Criteria

No award criteria specified; contract is awarded to all eligible participants who meet requirements.

Deadline

Deadline Feb 27, 2027

Procurement Details

Publication date
19 Jan 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
39458-2025

Documents (1)

Similar tenders